225. Congenital nephrogenic diabetes insipidus Clinical trials / Disease details
Clinical trials : 15 / Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05044611 (ClinicalTrials.gov) | April 1, 2022 | 27/8/2021 | AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium | AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled Trial | Bipolar Disorder | Drug: Anhydrous Amiloride Hydrochloride;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 148 | Phase 4 | NULL |